This program aims to develop anti-CD163 therapeutic monoclonal antibody for immuno-oncology.
Rationale when developing program:
In conclusion, M2 macrophages play a role in tumor progression by producing vascular endothelial growth factor and extracellular matrix remodeling proteins, highlighting the logic behind CD163-based cancer immunotherapy.
CD163, a member of the scavenger receptor cysteine (SRCR) superfamily, is the optimal marker for M2 macrophages. Some functions are highlighted below:
Fig.1 Ghemoglobin-haptoglobin-CD163 pathway in microglia/macrophages.1
Here are some published data about CD163 working as a potential target for cancer immunotherapy.
Fig.2 Association of CD163 expression at invasive front with the patients’ recurrence-free survival and overall survival in CRC.2
Fig.3 Survival analysis of CD163 in whole grade glioma and glioblastoma.3
We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Fig.4 Project pipeline management of therapeutic monoclonal antibody.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-CD163 Therapeutic Monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership. For any partners interest in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use